Wawruszak Anna, Halasa Marta, Okon Estera, Kukula-Koch Wirginia, Stepulak Andrzej
Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093 Lublin, Poland.
Department of Pharmacognosy, Medical University of Lublin, 20-093 Lublin, Poland.
Cancers (Basel). 2021 Jul 7;13(14):3409. doi: 10.3390/cancers13143409.
Valproic acid (2-propylpentanoic acid, VPA) is a short-chain fatty acid, a member of the group of histone deacetylase inhibitors (HDIs). VPA has been successfully used in the treatment of epilepsy, bipolar disorders, and schizophrenia for over 50 years. Numerous in vitro and in vivo pre-clinical studies suggest that this well-known anticonvulsant drug significantly inhibits cancer cell proliferation by modulating multiple signaling pathways. Breast cancer (BC) is the most common malignancy affecting women worldwide. Despite significant progress in the treatment of BC, serious adverse effects, high toxicity to normal cells, and the occurrence of multi-drug resistance (MDR) still limit the effective therapy of BC patients. Thus, new agents which improve the effectiveness of currently used methods, decrease the emergence of MDR, and increase disease-free survival are highly needed. This review focuses on in vitro and in vivo experimental data on VPA, applied individually or in combination with other anti-cancer agents, in the treatment of different histological subtypes of BC.
丙戊酸（2-丙基戊酸，VPA）是一种短链脂肪酸，属于组蛋白去乙酰化酶抑制剂（HDIs）。50多年来，VPA已成功用于治疗癫痫、双相情感障碍和精神分裂症。大量的体外和体内临床前研究表明，这种著名的抗惊厥药物通过调节多种信号通路显著抑制癌细胞增殖。乳腺癌（BC）是全球影响女性的最常见恶性肿瘤。尽管在BC治疗方面取得了显著进展，但严重的不良反应、对正常细胞的高毒性以及多药耐药（MDR）的出现仍然限制了BC患者的有效治疗。因此，迫切需要新的药物来提高当前治疗方法的有效性，减少MDR的出现，并延长无病生存期。本综述重点关注VPA单独或与其他抗癌药物联合应用于治疗不同组织学亚型BC的体外和体内实验数据。
